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Multidrug resistance phenotype in leukaemic cells from
patients with acute myelocytic leukaemia can be
detected with 99Tcm-MIBI
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Summary The aim of the study was to investigate whether 99Tcm-MIBI (Cardiolite), recently shown to be a substrate for P-glycoprotein, has
the potential to be used as a marker for mdrl gene expression and whether cyclosporin A (CyA) can modify its accumulation in vivo.
Leukaemic cells from ten patients with acute myelocytic leukaemia (AML) were used, five with undetectable mdrl gene expression and five
with mdrl mRNA levels ranging from 1.0 to 3.8 mdrl mRNA transcripts per cell. Cells were incubated with 99Tcm-MIBI, or with daunorubicin
(Dnr), with and without 3 ,UM CyA. The median 99Tcm-MIBI accumulation (% of added radioactivity) in mdrl-negative cells was 0.89% and in the
mdrl-positive cells 0.34%, P= 0.01. In mdrl-negative cells, the median increase in 99Tcm-MIBI accumulation with CyA was 30% compared
with the mdrl-positive cells with a median increase of 242%, P= 0.009. CyA had no significant effect on Dnr accumulation in four ofthe mdrl-
negative samples. The median increase of Dnr accumulation in the mdrl-positive cells was 40%. The results show that 99Tcm-MIBI with a high
sensitivity can detect rather low levels of mdrl gene expression in clinical samples. Consequently, 99Tcm-MIBI scintigraphy has the potential to
be used for monitoring the effect of resistance modifiers on the accumulation and retention of cytostatic drugs in human tumours in vivo.
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P-glycoprotein, encoded by the mdrl gene causes classical
multidrug resistance (MDR). This is characterized by resistance of
tumour cells to a wide variety ofanti-cancer drugs. P-glycoprotein
causes cellular efflux ofsuch drugs, a process that can be reversed
by so-called resistance modifiers, e.g. verapamil, cyclosporins and
quinidine (Fojo, 1991).
A large proportion of human tumour types have been investi-
gated for mdrl gene expression, which was initially described in
drug-selected cell lines. Acute leukaemias have been extensively
studied, and in several studies mdrl gene expression in acute
myelocytic leukaemia (AML) was an adverse prognostic factor
(Campos et al, 1992; Te Boekhorst et al, 1995; Leith et al, 1997).
However, there are also studies that could not confirm this finding
(Ino et al, 1994). Mdrl gene expression has also been detected in
lymphomas and in solid tumours, such as breast cancer, ovarian
cancer and osteosarcomas, but its relationship to treatment results
is less clear (Goldstein et al, 1992; Arao et al, 1994; Yuen and
Sikic, 1994; Lee et al, 1996; Linn et al, 1996). In small clinical
studies of AML and multiple myeloma, promising results have
been reported when resistance modifiers have been added to
chemotherapy, and trials are under way to investigate whether this
can improve treatment results (Sonneveld et al, 1992; List et al,
1993). Clinical studies in solid tumours are, so far, mostly phase I
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or contain few patients and are therefore not conclusive (Raderer
and Scheithauer, 1993).
More recently, it was shown that multidrug resistance can also
be conferred by the transport protein multidrug resistance-
associated protein (mrp) (Cole et al, 1992). Its clinical relevance is
still unclear but there have been studies that have demonstrated an
increase of mrp expression in relapsed AML (Hart et al, 1994;
Schneider et al, 1995).
The radiopharmaceutical 99Tcm-hexaxis-2-methoxyisobutyl iso-
nitrile (99Tcm-MIBI, 99Tcm-Sestamibi, Cardiolite), originally devel-
oped formyocardial scintigraphy, has been shown to be a substrate
for P-glycoprotein (Piwnica-Worms et al, 1993). In cell lines with
different levels ofP-glycoprotein expression, the accumulation of
99Tcm-MIBI and the effect of resistance modifiers were propor-
tional to the level of P-glycoprotein expression (Ballinger et al,
1995; Piwnica-Worms et al, 1995).
The level of mdrl gene expression in tumours is, however,
lower than in drug-selected cell lines. Using a quantitative
RNAase protection assay, we found the median level of mdrl
mRNA in positive cell samples from patients with AML to be
0.7 mdrl mRNA transcripts per cell (Gruber et al, 1992). In two
vincristine-selected K562 cell lines, the levels were approximately
100 and 200 transcripts per cell.
The aim of the present study was to investigate whether 99Tcm-
MIBI can be used to detect the rather low mdrl gene expression
found in human tumours. We therefore compared the accumulation
of99Tcm-MIBI and the effect ofcyclosporin A (CyA) in leukaemic
cell samples with and without mdrl gene expression. We also
investigated whether the effect of CyA on cellular 99Tcm-MIBI
accumulation was similar to the effect on daunorubicin (Dnr).
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1000- MATERIALS AND METHODS
Cell lines
The human leukaemic cell line K562, two vincristine-selected
sublines grown in 30 and 150 nM vincristine (K562/Vcr30,
K562/Vcrl50) and a mitoxantrone-resistant subline grown in
mitoxantrone 100 ng ml' (K562/Mxn) were used. K562/Vcr3O
and K562fVcrl50 expressed approximately 100 and 200 mdrl
mRNA transcripts per cell, respectively, as determined by a
quantitative RNAase protection assay (Gruber et al, 1992). Mdrl
mRNA was detected in solution with a [35S]UTP-labelled 403-
nucleotides antisense probe and quantification was performed by
comparison with a standard curve, generated by hybridizations
with increasing amounts of in vitro transcribed sense RNA. The
maternal line and K562/Mxn had no detectable mdrl mRNA.
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Leukaemic cells
Peripheral leukaemic cells from ten patients with AML were used.
Cells isolated on Lymphoprep (Nycomed, Pharma, AS, Norway)
were frozen in a programmed freezer and kept in liquid nitrogen.
The patients, peripheral white blood cell counts ranged from 32
to 363 x 109 1-1 (median 80 x 1091-'), and the percentage of
leukaemic cells was between 70% and 100% (median 90%). The
viability ofthe cells after thawing was controlled with trypan blue
exclusion and was 70% and 73% in two samples; in the remaining,
the viability was over 85%. The samples were chosen according to
their mdrl mRNA expression, which was determined earlier with
a quantitative RNAase protection assay (Gruber et al, 1992). Cells
from five of the patients had no detectable mdrl mRNA levels,
and cells from five patients had mdrl mRNA levels ranging from
1.0 to 3.8 mdrl mRNA transcripts per cell. That the function of
P-glycoprotein in thawed leukaemic cells is comparable to that in
fresh cells has been demonstrated by Broxterman and co-workers
(Broxterman et al, 1996).
The mdrl mRNA expression and also the mrp mRNA expres-
sion was reanalysed with a quantitative reverse transcription poly-
merase chain reaction (RT-PCR) method with some modifications
(Xu et al, 1996). By this method, the median mdrl mRNA expres-
sion in the samples found to be negative with the RNAase protec-
tion assay was 0.04 transcripts per cell (range 0.01-0.28) and in
the positive samples 8.8 transcripts per cell (range 1.4-15.8). Mrp
expression was positive in all samples, median 2.3 transcripts per
cell (range 0.5-4.0) in mdrl mRNA-negative samples and 3.1
transcripts per cell (range 1.5-4.2) in the mdrl mRNA-positive
samples, P = 0.2.
Incubation of cells with 99Tcm-MIBI and daunorubicin
From cell lines and patients, 0.5 and 1.0 x 106 cells, respectively,
were incubated in triplicates for 1 h at 37°C in 1 ml ofRPMI 1640
medium (Gibco, Glasgow, UK), supplemented with 10% newborn
calf serum and 2 mM L-glutamine, with 3-5 x 106 c.p.m. 99Tcm-
MIBI (Du Pont, Stevenage, UK). The incubations were performed
with and without CyA 3 gM (Sandoz, Basle, Switzerland). Cell
line cells were also incubated with higher concentrations of CyA
(10 and 20 gM). The incubations were stopped by centrifugation at
4°C for 5 min. After two washes with ice-cooled phosphate-
buffered saline (PBS), the activity of the cells was assessed with
a well-type gamma-counter (1282 Compugamma, LKB-Wallac,
Figure 1 Accumulation of 99Tcm-MIBI in K562 (- --), K562/Mxn
(0. ), K562Ncr30 (..........) and K562Ncr150 (A....) and effect of
CyA 3, 10 and 20gM. The cellular 99Tcm-MIBI accumulation is expressed as a
percentage of the accumulation in K562 without CyA
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Figure 2 (A) Accumulation of 99Tcm-MIBI in five mdrl mRNA-negative
leukaemic cell samples (median 0.89%) and in five with mdrl RNA levels
ranging from 1.0 to 3.8 transcripts per cell (median 0.34%), P = 0.012. The
cellular 99Tcm-MIBI accumulation is expressed as a percentage of added
radioactivity. (B) Per cent increase of 99Tcm-MIBI accumulation in mdrl
mRNA-negative (median 30%) and -positive (median 242%) samples with
3gM CyA, P= 0.009
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Bromma, Sweden). Correction was made fordecay of99Tcm during
the measuring time to obtain a maximal statistical uncertainty of
3%, indicated as one standard deviation.
Approximately 2.0 x 106 of the patient and cell line cells were
incubated in duplicates for 1.5 h at 37°C in 2 ml of medium
containing 1 gM Dnr with and without CyA 3 gM. Dnr incubations
were stopped by addition of 5 ml of ice-cooled PBS to the tubes
and centrifugation at 4°C for 5 min. After two washing steps with
PBS, the cellular Dnr content was analysed with high-performance
liquid chromatography (Baurin et al, 1978).
Statistical analyses
The differences in 99Tcm-MIBI and Dnr accumulation, and effects
of CyA in mdrl-negative and -positive patient samples were
analysed using the Mann-Whitney test. Correlations between the
effect of CyA on cellular 99Tcm-MIBI and Dnr accumulation were
analysed with linear regression analysis. A P-value of < 0.05 was
set as significant.
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Figure 3 Per cent increase of Dnr accumulation in mdrl mRNA-negative
(median 4%) and -positive (median 40%) samples with 3gM CyA, P= 0.12
RESULTS
Accumulation of 99Tcm-MIBI and daunorubicin in cell
line cells
K562 cells accumulated 3.1% ofadded 99Tcm-MIBI compared with
K562NVcr150, which accumulated only 0.06%. The accumulation
of 99Tcm-MIBI in K562/Vcrl5O cells was only 1.9% of that in
K562 and in K562/Vcr3O, 2.7% ofthat in K562. The accumulation
of 99Tcm-MIBI in the mitoxantrone-resistant cell line was equal to
that in the maternal line (Figure 1).
CyA 3 ,uM increased 99Tcm-MIBI accumulation in K562/Vcrl5O
with 662% from 1.9% to 14.5% ofthat in K562 without CyA, and
in K562/Vcr3O with 1342% from 2.7% to 37.3% of that in K562.
CyA, 10 and 20gM, further increased the 99Tcm-MIBI accumula-
tion in the resistant cell lines but not reaching the same level as in
K562. In the maternal line and in K562/Mxn, the increase caused
by CyA was the same at all three concentrations, approximately
40% and 50% respectively (Figure 1).
The accumulation of Dnr in K562/Vcrl5O was 29% of that in
K562. CyA 3 gM increased Dnr accumulation in the resistant line
to the same level as that in K562 without CyA. CyA 3 gM
increased Dnr accumulation with 13% in K562 cells (not shown).
Accumulation of 99Tcm-MIBI and daunorubicin in patient
leukaemic cells
The median accumulation of 99Tcm-MIBI in the five cell samples
from patients with undetectable mdrl mRNA expression was
0.89% of the input (range 0.73-1.39), compared with the five
samples positive for mdrl mRNA, which accumulated 0.34%
(range 0.15-0.73; P = 0.012) (Figure 2A).
The median increase in 99Tcm-MIBI accumulation caused by
CyA 3 gM in mdrl mRNA-negative samples was 30% (range
17-78) compared with the mdrl mRNA-positive samples, in
which the median increase was 242% (range 134-278; P = 0.009)
(Figure 2B).
The accumulation ofDnr in 2 x 106 patient cells varied between
0.21 and 0.97 nmol. There was a trend towards lower Dnr accumu-
lation in mdrl-positive samples compared with mdrl-negative
samples [mean 0.39 nmol (s.d. 0.215) vs 0.56 nmol (s.d. 0.285);
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Figure 4 Relationship between the effect of 3gM CyA on cellular
accumulation of Dnr and 99Tcm-MIBI in ten leukaemic cell samples, r= 0.45,
P= 0.19
P = 0.25]. The increase in Dnr accumulation with CyA 3 JM in
mdrl-negative cells was 74% in one sample. In the remaining four
it was 0, 4, 4 and 10%. The median increase of Dnr in the mdrl-
positive cells was 40% (range 19-68%; P = 0.11) (Figure 3).
In nine of the samples, there was a strong correlation between
the increase caused by CyA 3 JM on 99Tcm-MIBI and Dnr
accumulation (r = 0.87, P = 0.0023). Because of a large effect on
Dnr accumulation (74% increase) in one mdrl-negative sample,
the correlation was not statistically significant for all ten samples,
P = 0.19 (Figure 4).
DISCUSSION
The results of this study show that the difference in cellular 9Tcm-
MIBI accumulation between K562 and the mdrl gene-expressing
K562/Vcrl5O was much larger than the difference in Dnr accumu-
lation. 99Tcm-MIBI accumulation in KS62Ncrl50 was only 1.9%
ofthat in K562 compared with Dnraccumulation, which was 29%.
CyA 3 gM restored Dnr accumulation in K562Ncrl5O to the same
British Journal ofCancer (1998) 77(11), 1732-1736
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level as that in the maternal line, while 99Tcm-MIBI by the same
CyA concentration was increased to only 14.5% of that in K562.
Consistent with the results of Piwnica-Worms and co-workers
(1993), the increase in 99Tcm-MIBI accumulation caused by CyA
3 FtM was larger in K562Ncr3O, with a lower degree ofresistance
than in K562/Vcrl50. The results confirm the very high affinity of
99Tcm-MIBI to P-glycoprotein and its high sensitivity to detect
P-glycoprotein expression.
The high affinity of99Tcm-MIBI to P-glycoprotein is confirmed
by the fact that the cellular accumulation of99Tcm-MIBI was much
lower in the mdrl gene-expressing human leukaemic cell samples
than in the samples with undetectable mdrl expression. In
contrast, for Dnr, there was only a non-significant trend towards
lower accumulation in mdrl-positive than in mdrl-negative
samples. In parallel, the increase in cellular accumulation caused
by CyA in mdrl-positive samples was much larger for99Tcm-MIBI
than forDnr (median 242% vs 40%). Although the increase caused
by CyA 3 gM was much largerfor99Tc--MIBI than forDnr, in nine
of the samples there was a correlation between the effect on the
two, which is a prerequisite for the use of 99Tcm-MIBI in vivo for
functional monitoring of P-glycoprotein activity. In one mdrl
mRNA-negative sample, CyA 3 gM increased the cellular Dnr
accumulation by 74%, while the increase for 99Tc--MIBI was only
18%. One explanation for this discrepancy could be the existence
ofother transport proteins for which 99Tcm-MIBI is not a substrate.
Dnr is also transported by mrp. Whether 99Tcm-MIBI is a substrate
for mrp is unknown. However, all our samples were positive for
mrp expression, in the case in question four transcripts per cell.
Moreover, CyA was shown to be arather poor modifier ofreduced
Dnr accumulation in mrp-positive cells (Barrand et al, 1993).
Consequently, it seems likely that the increase in Dnr accumula-
tion caused by CyA in this sample is a result ofmechanisms other
than mrp expression.
The potential use of 99Tcm-MIBI as a marker for P-glycoprotein
and the effect of resistance modifiers in vivo has recently been
demonstrated by Luker and co-workers (1997). 99Tcm-MIBI scintig-
raphy with and without the resistance modifier PSC-833, a
cyclosporin D analogue, was performed on three patients. With
administration of the modifier, 99Tcm-MIBI was selectively retained
in theliverandkidneys, two organs withhigh expression ofP-glyco-
protein. In a study ofpatients with untreated breastcancer, the efflux
rate of 99Tcm-MIBI was faster from tumours with high than from
those with low P-glycoprotein expression (Vecchio et al, 1997).
The results of 99Tcm-MIBI scintigraphy before chemotherapy
have also been related to treatment response in a few patients with
breast cancer (Moretti et al, 1996) and malignant lymphomas.
Kapucu and co-workers (1997) found, in a study of24 children with
untreated malignant lymphomas, that children with positive scans
responded better to chemotherapy than those with negative scans.
The results oftrials in solid tumours when resistance modifiers
were added to chemotherapy are often difficult to interpret. Only
some patients seem to respond (Raderer and Scheithauer, 1993).
An assay that can monitor P-glycoprotein function and the effect
of resistance modifiers would be a tool to select, for example,
patients with malignant lymphoma who may benefit from addition
ofresistance modifiers to chemotherapy (Miller et al, 1991; Sarris
et al, 1996).
In summary, our results show that 99Tcm-MIBI is very sensitive
in detecting mdrl gene expression at the low, but probably clini-
cally relevant, levels that are present in human tumour cells.
Secondly, the effect ofCyA 3 gM on cellular 99Tcm-MIBI accumu-
lation seems to reflect the effect on cytostatic drugs (at least
daunorubicin).
99Tcm-MIBI is a well-established radiopharmaceutical for
myocardial scintigraphy used routinely world-wide since about
1990. As is the case for most radiopharmnaceuticals, the amount of
chemical substrate administered is very low, and adverse reactions
are rare. The effective dose equivalent of a typical administered
activity of 500 MBq is 7 mSv compared with approximately
5 mSv for an abdominal computerized tomography examination.
Consequently, 99Tcm-MIBI scintigraphy has the potential of
being used to monitor the effect of resistance modifiers on the
accumulation and retention ofcytostatic drugs in human tumours,
e.g. lymphomas, in vivo. The use of 99Tcm-MIBI scintigraphy in
clinical trials in which resistance modifiers are added to
chemotherapy will answer whether it can be used to predict the
efficacy ofsuch treatment.
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